FDA approves perioperative Imfinzi-Padcev regimen in bladder cancer
FDA approval gives cisplatin-ineligible or cisplatin-refused MIBC patients a perioperative Imfinzi-Padcev option; VOLGA showed a 49% event-risk cut and 42% lower mortality.

Stories
U/AUTHOR
12 filings logged
FDA approval gives cisplatin-ineligible or cisplatin-refused MIBC patients a perioperative Imfinzi-Padcev option; VOLGA showed a 49% event-risk cut and 42% lower mortality.
